Swiss Archives of Neurology Psychiatry and Psychotherapy
May 18, 2024
Helena Aicher, Peter Gasser
17 citations
Switzerland's early contributions to the 'psychedelic renaissance', the revival of psychedelic science starting in the early 21st century, might be particularly noteworthy given the growing global interest in using psychedelics for research and therapy.In 2023, the Swiss Interest Group for Psychedelic-assisted Therapy was established to provide a clear and widely accepted framework for work...
Nervenheilkunde
May 14, 2024
Jörg Daumann, Uwe Herwig
ZUSAMMENFASSUNG Die Anwendung von Psychedelika in der Psychotherapie wirft erhebliche ethische, soziale und klinische Fragen auf. Gesundheitliche Risiken, Spezifika des Informed Consent, medialer Einfluss, die Rolle der Therapeuten, Sicherheitsaspekte und der rechtliche Status sind exemplarische Schlüsselbereiche. Auch in der wissenschaftlichen Evaluation der psychedelikaaugmentierten...
Neuropsychopharmacology
May 13, 2024
Conor H. Murray
MDMA-assisted psychotherapy has emerged as a potential treatment for psychiatric illnesses, with findings from clinical trials in the last decade demonstrating safety and efficacy in the treatment of posttraumatic stress disorder (PTSD), among other psychiatric indications. Earlier this year (2024), the Food and Drug Administration in the United States granted priority review for a new drug...
May 2, 2024
Prince Patel, Samrat Gollapudi, Brian Joseph Mathew et al.
Psychedelic-assisted psychotherapy (PAP) has shown promising therapeutic benefits for various psychiatric disorders, but the underlying neural mechanisms remain unclear. This study aimed to investigate the effects of psychedelics on brain connectivity patterns using functional magnetic resonance imaging (fMRI). A comprehensive literature search was conducted in PubMed and Google Scholar...
Journal of Psychoactive Drugs
May 2, 2024
Dave Rojas, Diane C Zelman, Alexander O Hauson et al.
2 citations
Black, Indigenous, and People of Color (BIPOC), and other minoritized populations are insufficiently represented in research on therapeutic psychedelics. This research was a phenomenological qualitative exploration of a culturally diverse (Hispanic, African American, Asian, Native American, biracial, or LGBTQIA+) and low-income sample of 15 individuals receiving ketamine-assisted psychotherapy...
Psychiatry Research
May 1, 2024
Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al.
48 citations
Psychotherapies assisted by psychedelic substances have shown promising results in the treatment of psychiatric disorders. The aim of this systematic review and meta-analysis was to evaluate safety data in human subjects. We carried out a search on MEDLINE, Embase and PsycINFO databases between 2000 and 2022. Standardized mean differences between different dose ranges and between acute and...
EMBARK Psychedelic Therapy for Depression
April 23, 2024
Bill Brennan, Alex Belser
AbstractChapter 1 introduces the concept of psychedelic-assisted therapy (PAT) and the EMBARK psychedelic therapy model, a new approach to PAT and psychological support. The chapter serves as an orientation to the book, outlining its structure and intended audiences. It discusses the growing interest in psychedelic medicines for treating mental health disorders, particularly depression. The...
Journal of Psychopharmacology
April 23, 2024
Evan Cole Lewis, Alexandria Jaeger, Manesh Girn et al.
6 citations
Functional seizures (FS), the most common subtype of functional neurological disorder (FND), cause serious neurological disability and significantly impact quality of life. Characterized by episodic disturbances of functioning that resemble epileptic seizures, FS coincide with multiple comorbidities and are treated poorly by existing approaches. Novel treatment approaches are sorely needed....
Neuropsychopharmacology
April 23, 2024
Julia Colcott, Olivia Carter, Sally Meikle et al.
37 citations
Abstract Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted the first comprehensive systematic review and meta-analysis of the side effects of MDMA-AP across indications. We also assessed the quality of side effects-reporting in published trials of MDMA-AP. PubMed, EMBASE, PsycINFO, MEDLINE and Cochrane...
Frontiers in Pain Research
April 19, 2024
Maya Armstrong, Joel Castellanos, Devon Christie
15 citations
Despite research advances and urgent calls by national and global health organizations, clinical outcomes for millions of people suffering with chronic pain remain poor. We suggest bringing the lens of complexity science to this problem, conceptualizing chronic pain as an emergent property of a complex biopsychosocial system. We frame pain-related physiology, neuroscience, developmental...
Frontiers in Psychiatry
April 18, 2024
Gina Micciche, Andrew McMillan, Emily Coughlin et al.
4 citations
Introduction Patients with incurable illnesses often experience existential distress, profoundly impacting their well-being. Current medical approaches have limitations in addressing these burdens. Psilocybin, a promising psychedelic compound, may offer therapeutic benefits. This pilot survey study aimed to investigate the attitudes and openness toward psilocybin-assisted psychotherapy (PAT)...
JMIR Research Protocols
April 17, 2024
Akash Goel, Bhavya Kapoor, Hillary Chan et al.
2 citations
Chronic pain affects approximately 8 million Canadians (~20%), impacting their physical and mental health while burdening the health care system with costs of upwards of US $60 billion a year. Indeed, patients are often trialed on numerous medications over several years without reductions to their symptoms. Therefore, there is an urgent need to identify new therapies for chronic pain to improve...
Australian & New Zealand Journal of Psychiatry
April 16, 2024
Samuel P Hatfield, Nicollette Lr Thornton, Kayla Greenstien et al.
9 citations
Objectives: The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change has raised various regulatory concerns and challenges for the field of psychedelic-assisted therapy. To provide clarity, we aimed to comprehensively catalogue the matters relating to psychedelic-assisted therapy that are or could be regulated....
Journal of Psychedelic Studies
April 2, 2024
Sonia M. Brodie, Chelsea Stunden, Jay A. Olson et al.
AbstractBackground and aimsFirst responders such as firefighters and police officers often experience traumatic events as part of their work. As a result, they are more likely to have mental health issues such as post-traumatic stress disorder, depression, and anxiety compared to the general population. Psychedelic-assisted therapy has emerged as a promising avenue to alleviate these issues,...
European Psychiatry
April 1, 2024
V. Tsang
IntroductionDepression continues to present significant economic burdens to the Canadian healthcare system. Novel therapies, including those that incorporate psychoactive substances such as ketamine, present an opportunity to evaluate both clinical and economic effectiveness against current standards of care, which may be repeatedly proving ineffective in treating depression for some...
International Journal of Mental Health and Addiction
April 1, 2024
Joseph T. Torre, Mehdi Mahammadli, Sonya C. Faber et al.
31 citations
Currently, individuals with personal or familial histories of psychopathological experiences of psychosis, psychotic spectrum disorders, bipolar disorder, and similar conditions are excluded from most psychedelic clinical trials, studies, and treatment programs. This study sought to determine why such an exclusion exists, what the implications of the exclusion criteria are, and if there was...
European Psychiatry
April 1, 2024
N. Kabir, B. Anderson, Lisa Bouchet et al.
1 citation
Introduction Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, LSD, MDMA and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential distress and post-traumatic stress disorder. Objectives...
European Psychiatry
April 1, 2024
Shannon Dames, Crosbie Watler, P. Kryskow et al.
1 citation
Introduction This review explores the benefits of incorporating personal experience(s) with non-ordinary states of consciousness as a core component of Psychedelic-Assisted Therapy (PaT) training.The program incorporates an optional experiential training component. We collaborate with professionals affiliated with a Canadian non-profit organization specializing in PaT experiential training. As...
Journal of Affective Disorders
April 1, 2024
Sabrina Wong, Angela T H Kwan, Kayla M Teopiz et al.
19 citations
Inadequate outcomes with monoamine-based treatments in depressive disorders are common and provide the impetus for mechanistically-novel treatments. Esketamine is a proven treatment recently approved for adults with Treatment-Resistant Depression (TRD) while psilocybin is an investigational treatment. Translation of the clinical meaningfulness for these foregoing agents in adults with TRD is...
Journal of Behavioral Addictions
March 26, 2024
Pedro Romero, Andrea Czakó, Wim van den Brink et al.
7 citations
Abstract Gambling disorder is a severe mental health and behavioural problem with harmful consequences, including financial, relationship and mental health problems. The present paper initiates discussion on the use of psychedelics combined with psychotherapeutic support as a potential treatment option for people living with a gambling disorder. Recent studies have shown promising results using...